Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial
- PMID:25545858
- DOI: 10.1001/jamainternmed.2014.6916
Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial
Erratum in
- Error in Table.[No authors listed][No authors listed]JAMA Intern Med. 2016 Jan;176(1):143. doi: 10.1001/jamainternmed.2015.7309.JAMA Intern Med. 2016.PMID:26747676No abstract available.
Abstract
Importance: Standard varenicline tartrate dosing was formulated to avoid adverse effects (primarily nausea), but some patients may be underdosed. To our knowledge, no evidence-based guidance exists for physicians considering increasing varenicline dose if there is no response to the standard dosage.
Objective: To determine whether increasing varenicline dose in patients showing no response to the standard dosage improves treatment efficacy.
Design, setting, and participants: In a double-blind randomized placebo-controlled trial, 503 smokers attending a stop smoking clinic commenced varenicline use 3 weeks before their target quit date (TQD). Two hundred participants reporting no strong nausea, no clear reduction in smoking enjoyment, and less than 50% reduction in their baseline smoking on day 12 received additional tablets of varenicline or placebo.
Interventions: All participants began standard varenicline tartrate dosing, gradually increasing to 2 mg/d. Dose increases of twice-daily varenicline (0.5 mg) or placebo took place on days 12, 15, and 18 (up to a maximum of 5 mg/d).
Main outcomes and measures: Participants rated their smoking enjoyment during the prequit period and withdrawal symptoms weekly for the first 4 weeks after the TQD. Continuous validated abstinence rates were assessed at 1, 4, and 12 weeks after the TQD.
Results: The dose increase reduced smoking enjoyment during the prequit period, with mean (SD) ratings of 1.7 (0.8) for varenicline vs 2.1 (0.7) for placebo (P = .001). It had no effect on the mean (SD) frequency of urges to smoke at 1 week after the TQD, their strength, or the severity of withdrawal symptoms: these ratings for varenicline vs placebo were 2.7 (1.1) vs 2.6 (0.9) (P = .90), 2.6 (1.1) vs 2.8 (1.0) (P = .36), and 1.5 (0.4) vs 1.6 (0.5) (P = .30), respectively. The dose increase also had no effect on smoking cessation rates for varenicline vs placebo at 1 week (37 [37.0%] vs 48 [48.0%], P = .14), 4 weeks (51 [51.0%] vs 59 [59.0%], P = .32), and 12 weeks (26 [26.0%] vs 23 [23.0%], P = .61) after the TQD. There was significantly more nausea (P < .001) and vomiting (P < .001) reported in the varenicline arm than in the placebo arm.
Conclusions and relevance: Increasing varenicline dose in smokers with low response to the drug had no significant effect on tobacco withdrawal symptoms or smoking cessation. Physicians often consider increasing the medication dose if there is no response to the standard dosage. This approach may not work with varenicline.
Trial registration: clinicaltrials.gov Identifier:NCT01206010.
Comment in
- Improving the success of treating tobacco smokers.Rigotti NA.Rigotti NA.JAMA Intern Med. 2015 Feb;175(2):272-3. doi: 10.1001/jamainternmed.2014.6921.JAMA Intern Med. 2015.PMID:25545347No abstract available.
Similar articles
- Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial.Hajek P, Smith KM, Dhanji AR, McRobbie H.Hajek P, et al.BMC Med. 2013 May 29;11:140. doi: 10.1186/1741-7015-11-140.BMC Med. 2013.PMID:23718718Free PMC article.Clinical Trial.
- Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR.Hajek P, et al.Arch Intern Med. 2011 Apr 25;171(8):770-7. doi: 10.1001/archinternmed.2011.138.Arch Intern Med. 2011.PMID:21518946Clinical Trial.
- Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial.Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, Hurt RD.Ebbert JO, et al.JAMA. 2014 Jan 8;311(2):155-63. doi: 10.1001/jama.2013.283185.JAMA. 2014.PMID:24399554Free PMC article.Clinical Trial.
- Varenicline: a first-line treatment option for smoking cessation.Garrison GD, Dugan SE.Garrison GD, et al.Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021.Clin Ther. 2009.PMID:19393839Review.
- Nicotine receptor partial agonists for smoking cessation.Cahill K, Stead LF, Lancaster T.Cahill K, et al.Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5.Cochrane Database Syst Rev. 2011.Update in:Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103. doi: 10.1002/14651858.CD006103.pub6.PMID:21328282Updated.Review.
Cited by
- Abstinence Rate, Adverse Events and Withdrawal Symptoms after Varenicline Use and Predicting Factors of Smoking Abstinence: A Multicentre Single-State Study in Malaysia.Choo SJ, Chang CT, Tangiisuran B, Latif MFA, Sanusi NA, Harun SN.Choo SJ, et al.Int J Environ Res Public Health. 2022 Jun 24;19(13):7757. doi: 10.3390/ijerph19137757.Int J Environ Res Public Health. 2022.PMID:35805417Free PMC article.
- Does cigarette reduction while using nicotine replacement therapy prior to a quit attempt predict abstinence following quit date?Lindson-Hawley N, Shinkins B, West R, Michie S, Aveyard P.Lindson-Hawley N, et al.Addiction. 2016 Jul;111(7):1275-82. doi: 10.1111/add.13330. Epub 2016 Mar 16.Addiction. 2016.PMID:26990374Free PMC article.
- Improvement of Smoking Abstinence Rates With Increased Varenicline Dosage: A Propensity Score-Matched Analysis.Karam-Hage M, Kypriotakis G, Robinson JD, Green CE, Mann G, Rabius V, Wippold R, Blalock JA, Mouhayar E, Tayar J, Chaftari P, Cinciripini PM.Karam-Hage M, et al.J Clin Psychopharmacol. 2018 Feb;38(1):34-41. doi: 10.1097/JCP.0000000000000829.J Clin Psychopharmacol. 2018.PMID:29232312Free PMC article.
- Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis.Karelitz JL, McClure EA, Wolford-Clevenger C, Pacek LR, Cropsey KL.Karelitz JL, et al.Drug Alcohol Depend. 2021 Apr 1;221:108570. doi: 10.1016/j.drugalcdep.2021.108570. Epub 2021 Feb 3.Drug Alcohol Depend. 2021.PMID:33592559Free PMC article.Review.
- Nicotine receptor partial agonists for smoking cessation.Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N.Livingstone-Banks J, et al.Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.Cochrane Database Syst Rev. 2023.PMID:37142273Free PMC article.Review.
Publication types
MeSH terms
Substances
Associated data
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical